Program
LY03020
A development code.
Its studies are mostly in Schizophrenia, led by Luye Pharma Group.
Furthest: phase 2, since Feb 2, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Luye Pharma Group | 43 open or running | phase 2since Feb 2, 2026 | Aug 13, 2024 | Dec 31, 2027phase 2 · NCT07396870 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 13, 2024First study: phase 1 study in SchizophreniaFirst studyNCT06556966 · 66 enrolled · China
- Aug 6, 20252 phase 1 studies in SchizophreniaNCT07292233, NCT07230652
- Feb 2, 2026Phase 2 study in SchizophreniaPhase 2 reachedNCT07396870 · 160 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in SchizophreniaNCT07396870
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07396870Schizophrenia · China | 2 | Not yet recruiting | Dec 31, 2027 | 160 |
| NCT07292233Schizophrenia · China | 1 | Active, not recruiting | Aug 27, 2025 | 16 |
| NCT07230652Schizophrenia · China | 1 | Recruiting | Dec 31, 2025 | 40 |
| NCT06556966Schizophrenia · China | 1 | Completed | Feb 13, 2025 | 66 |
How it is read
Names in the registry
- “LY03020”, 4 entries
Codes read as this program: LY03020.
Conditions, from the studies’ own filings
- Schizophrenia, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.